| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Chain Expression or STAT5 Activation
,¶
,
,,¶
* Benaroya Research Institute, Virginia Mason, Seattle, WA;
Department of Immunology,
Washington National Primate Center, and
Department of Otolaryngology-Head and Neck Surgery, University of Washington School of Medicine, Seattle, WA; and
¶ Fred Hutchinson Cancer Research Center, Seattle, WA
Major gains in the efficacy of T cell-based therapies for cancer and infectious diseases could be realized through improved understanding of the signals that control expansion and differentiation of CD8+ cytolytic T cells. IL-2, IL-15, and the downstream transcription factor STAT5 have all been implicated as important regulators of these processes, yet there are conflicting data regarding their contribution to in vivo T cell responses. We used a murine adoptive T cell transfer model to examine the contribution of IL-2 and IL-15 signaling to the proliferation and differentiation of naive, CD8+ T cells bearing an OVA-specific TCR transgene (OT-I). OT-I T cells failed to express the high affinity IL-2R (CD25) while proliferating in vivo, irrespective of the mode of Ag delivery. Moreover, OT-I T cells rendered genetically deficient in the shared IL-2/IL-15R
subunit (IL-2R) demonstrated normal Ag-induced proliferation and cytolytic activity in vivo. Accordingly, activation of STAT5 was not detected in proliferating IL-2R-deficient OT-I T cells, thus implicating a STAT5-independent cytokine or costimulatory pathway in this process. Even though IL-2 and IL-15 were dispensable for CD8+ T cell proliferation, systemic infusion of IL-2 nevertheless promoted the expansion of OT-I T cells in vivo. Thus, IL-2 and IL-15 signals are not essential for CD8+ T cell proliferation or differentiation, but IL-2 can promote supraphysiological expansion when supplied exogenously. These findings challenge current models that place CD8+ T cell proliferation under the control of STAT5-dependent cytokines and suggest new approaches to the therapeutic manipulation of T cell numbers in vivo.
This article has been cited by other articles:
|
|
 |
|
  T. Yang, E. M. Wall, K. Milne, P. Theiss, P. Watson, and B. H. Nelson CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism Clin. Cancer Res., December 1, 2007; 13(23): 7172 - 7180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oizumi, N. Strbo, S. Pahwa, V. Deyev, and E. R. Podack Molecular and Cellular Requirements for Enhanced Antigen Cross-Presentation to CD8 Cytotoxic T Lymphocytes J. Immunol., August 15, 2007; 179(4): 2310 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kamimura and M. J. Bevan Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo J. Exp. Med., August 6, 2007; 204(8): 1803 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yu and T. R. Malek Selective Availability of IL-2 Is a Major Determinant Controlling the Production of CD4+CD25+Foxp3+ T Regulatory Cells J. Immunol., October 15, 2006; 177(8): 5115 - 5121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Antony, C. M. Paulos, M. Ahmadzadeh, A. Akpinarli, D. C. Palmer, N. Sato, A. Kaiser, C. Heinrichs, C. A. Klebanoff, Y. Tagaya, et al. Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo J. Immunol., May 1, 2006; 176(9): 5255 - 5266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jin, D. Gong, D. Adeegbe, A. L. Bayer, C. Rolle, A. Yu, and T. R. Malek Quantitative assessment concerning the contribution of IL-2R{beta} for superantigen-mediated T cell responses in vivo Int. Immunol., April 1, 2006; 18(4): 565 - 572. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
